Leading Cannabis Researchers

Hebrew University of Jerusalem

Jerusalem, Israel

Endocannabinoid system biology; novel cannabinoid synthesis; neuroprotection; anti-inflammatory mechanisms; cannabinoid pharmacology

Icahn School of Medicine at Mount Sinai

New York, NY

CBD for opioid use disorder; prenatal cannabis exposure and neurodevelopment; addiction neurobiology; striatal dopamine circuits; epigenetic mechanisms of addiction

NYU Langone Health

New York, NY

CBD for treatment-resistant epilepsy; Dravet syndrome; Lennox-Gastaut syndrome; SUDEP prevention; cannabinoid mechanisms in seizure suppression

Canopy Growth Corporation / McGill University

Montreal, Canada

Cannabis for chronic neuropathic pain; long-term safety of medical cannabis; cannabis pharmacokinetics; cannabis policy; patient-reported outcomes in pain

Université Laval

Quebec City, Canada

Endocannabinoidome; gut microbiome-endocannabinoid interactions; metabolic disease; obesity; lipid mediators; 2-AG and anandamide biosynthesis/degradation

University of California, Los Angeles

Los Angeles, CA

Cannabis pharmacology in humans; CBD-THC interactions; cannabis for pain and opioid-sparing; cannabis and cognition; cannabis use disorder; regulatory science

CReDO Science

Vashon Island, WA

Entourage effect; terpene pharmacology; clinical endocannabinoid deficiency; cannabis for pain and migraine; ethnobotany of cannabis; whole-plant cannabis medicine

University of California, San Francisco / Zuckerberg San Francisco General Hospital

San Francisco, CA

Cannabis for cancer-related symptoms (pain, nausea, anorexia); HIV-associated neuropathy; integrative oncology; cannabis-drug interactions in cancer patients; palliative care

University of California, Irvine

Irvine, California, USA

Endocannabinoid signaling mechanisms, FAAH and MAGL inhibitors as therapeutic targets, lipid neurotransmission, anandamide pharmacology, and non-intoxicating cannabinoid-based drug development.

University of California, San Diego

San Diego, California, USA

Clinical trials of medicinal cannabis for pain and neurological conditions, neuropsychiatric effects of HIV, cognitive consequences of cannabis use, and regulatory science for cannabis research.

University of Wollongong

Wollongong, New South Wales, Australia

Long-term cognitive effects of cannabis use, neuroimaging of cannabis-related brain changes, age-of-onset effects, CBD neuroprotection against THC, and cannabis use disorder treatment.

McLean Hospital / Harvard Medical School

Belmont, Massachusetts, USA

Neuroimaging of cannabis effects on brain structure and function, medical vs. recreational cannabis outcomes, cognitive effects of cannabis across the lifespan, and neurobiological markers of cannabis use disorder.

Medical College of Wisconsin

Milwaukee, Wisconsin, USA

Endocannabinoid biochemistry, stress-ECS interactions, circulating endocannabinoid biomarkers, PTSD and anxiety neurobiology, and sex differences in cannabinoid pharmacology.

University of Aberdeen

Aberdeen, Scotland, UK

Cannabinoid receptor pharmacology, mechanisms of action of THC and CBD, allosteric modulation of CB1 receptors, inverse agonists and neutral antagonists, and cannabinoid-based drug development.

AIMS Institute

Seattle, Washington, USA

Cannabis in palliative and end-of-life care, cancer symptom management, integrative oncology, cannabis policy and access, and the history of cannabis medicine.

University of California, San Diego

San Diego, California, USA

Cannabinoid clinical trials for neuroinflammatory conditions, endocannabinoid system and gut microbiome interactions, MS and TBI treatment, and integrative approaches to neurological disease.

Washington University in St. Louis

St. Louis, Missouri, USA

Cannabinoid-opioid interactions in pain circuits, opioid-sparing effects of cannabis, sex differences in cannabinoid pharmacology, neural mechanisms of cannabinoid analgesia, and cannabis policy.

International Association for Cannabinoid Medicines

Rüthen, Germany

Cannabis pharmacokinetics, clinical applications of cannabinoid medicines, medical cannabis policy, driving under the influence of cannabis, and patient education.

Université Laval

Quebec City, Quebec, Canada

Endocannabinoid system in metabolic disease and obesity, gut microbiome-endocannabinoidome axis, 2-AG pharmacology, endocannabinoid-related lipid mediators, and the expanded endocannabinoidome.

Harvard Medical School

Boston, Massachusetts, USA

Medical cannabis history and policy, patient-reported outcomes, psychiatric applications of cannabis, and the social and political dimensions of cannabis prohibition.